The agency is recommending that the market authorization for Oxbryta (voxelotor) be suspended so that emerging data may be reviewed.
EMA Suspends Sickle Cell Disease Medicine
The agency is recommending that the market authorization for Oxbryta (voxelotor) be suspended so that emerging data may be reviewed.
